

1 **Title:** Proteolytic queues at ClpXP increase antibiotic tolerance

2 **Authors:**

3 Heather S. Deter^{‡1}, Alawiah H. Abualrahi^{‡1}, Prajakta Jadhav¹, Elise K. Schweer¹, Curtis T. Ogle²,
4 and Nicholas C. Butzin*¹

5 **Affiliations:**

6 1. Department of Biology and Microbiology. South Dakota State University. Brookings, SD.
7 57006. USA.

8 2. Independent researcher. Prosser, WA, 99350. USA.

9 [‡] Authors contributed equally

10 *Corresponding author

11 Nicholas C. Butzin

12 South Dakota State University

13 Department of Biology and Microbiology

14 1224 Medary Ave.

15 Brookings, SD. 57007, USA

16 Email: nicholas.butzin@gmail.com

17 Phone: 605-688-4078

18 Fax: 605-688-6677

19 **Keywords:** antibiotic tolerance, persistence, antibiotic resistance, queueing, protease, synthetic
20 biology, ClpXP

21 **Abstract**

22 Antibiotic tolerance is a widespread phenomenon that renders antibiotic treatments less
23 effective and facilitates antibiotic resistance. Here we explore the role of proteases in antibiotic
24 tolerance, short-term population survival of antibiotics, using queueing theory (i.e. the study of
25 waiting lines), computational models, and a synthetic biology approach. Proteases are key cellular
26 components that degrade proteins and play an important role in a multi-drug tolerant subpopulation
27 of cells, called persisters. We found that queueing at the protease ClpXP increases antibiotic
28 tolerance ~80 and ~60 fold in an *E. coli* population treated with ampicillin and ciprofloxacin,
29 respectively. There does not appear to be an effect on antibiotic persistence, which we distinguish
30 from tolerance based on population decay. These results demonstrate that proteolytic queueing is
31 a practical method to probe bacterial tolerance and related genes, while limiting the unintended
32 consequences frequently caused by gene knockout and overexpression.

33 **Article**

34 The discovery of penicillin in the 1920s led to a new age of human and animal medicine as
35 many antibiotics were quickly identified and developed, but the subsequent explosion of antibiotic
36 treatments and applications has simultaneously driven microbial evolution and the development
37 of widespread resistance^{1,2}. A significant contributing factor to the abundance of antibiotic-
38 resistant microorganisms is survival of antibiotic treatment due to antibiotic tolerance and
39 persistence^{3,4}. Persistence is a physiological state that enables cells to survive antibiotic treatment
40 via temporary changes in phenotype, such as slowed growth and biosynthesis, rather than genotype
41 (e.g. antibiotic resistance)⁵. Although persistence has been studied for over 70 years, there has
42 been a lack of specificity in the literature between antibiotic tolerance and persistence^{5,6}. Recently,
43 a consensus statement that was released after a discussion panel with 121 researchers defined

44 antibiotic persistence as a tolerant subpopulation of cells that result in a distinct phase of population
45 decay⁵. We use population decay rates to differentiate between antibiotic tolerance and persistence
46 in this work (Fig. 1A).

47 The widespread nature of persistence suggests that similar mechanisms exist to trigger the
48 persistent state in prokaryotes. These mechanisms include many common systems, including
49 toxin-antitoxin (TA) systems and proteases. Although the precise role of TA systems in persistence
50 is unclear, toxins in TA systems can trigger persistence when at a higher level than their cognate
51 antitoxin⁷⁻⁹. Within the cell, the ratio of toxin to antitoxin is regulated during protein production¹⁰⁻
52 ¹² and through degradation by proteases^{13,14}. Proteases, such as Lon and ClpP, are largely
53 responsible for protein degradation and cell maintenance^{15,16}. They provide an essential level of
54 protein regulation throughout the cell, including degradation of RpoS (a transcription factor that
55 responds to stress)¹⁷ and polypeptides (incomplete proteins) synthesized by stalled ribosomes that
56 have been rescued by the trans-translation system¹⁸. In *E. coli*, *ssrA* (tmRNA) and *smpB* are the
57 genes responsible for trans-translation, the cellular mechanism for recovering stalled ribosomes.
58 A tmRNA molecule acts as a tRNA by binding to the A-site of a stalled ribosome and a protein-
59 coding region that adds an amino acid tag (LAA) to target the polypeptide for degradation by
60 ClpXP¹⁸. While *ssrA* is not essential in *E. coli*, *ssrA* knockouts cause growth defects, increase
61 susceptibility to certain antibiotics¹⁹, and affect persistence^{20,21}. Proteases and related chaperones
62 are also consistently identified as persister related genes in gene knockout experiments^{22,23} and
63 transcriptome analysis²⁴. Indeed, a drug that targets persisters, acyldepsipeptide (ADEP4),
64 activates the protease ClpP and lowers persister levels²⁵. Most published articles focus on methods
65 that reduce persister levels, but conditions that increase their levels are integral to understanding
66 the causative mechanisms of action and developing new drugs. As many persister studies

67 incidentally examine antibiotic tolerance^{5,6}, it follows that some of these mechanisms may also
68 play a role in antibiotic tolerance.

69 Synthetic biology takes advantage of these components to develop new cellular circuits. For
70 example, synthetic oscillators require rapid degradation of proteins, which is accomplished using
71 the LAA degradation tag derived from *ssrA*²⁶⁻²⁸. Previous work establishes that multiple circuits
72 can be coordinated by overproduction of a degradation tag used by those circuits to target proteins
73 to a protease^{29,30}. When a protease is overloaded, protein species compete for degradation; the
74 enzyme is unable to keep up with the influx of new proteins³¹. This phenomenon can be explained
75 by queueing theory, the study of waiting lines (in which one type of customer competes for
76 processing by servers), which has traditionally been applied to systems such as computer networks
77 and call centers. Limited processing resources (e.g. proteases) in a cell cause biological queues
78 (enzymatic bottlenecks)^{28,32} (Fig. 1B). The coupling of otherwise independent synthetic systems
79 demonstrates that queueing affects protein degradation and thus provides a tunable method of
80 studying proteolytic degradation with little effect on cell growth^{28-30,32} compared to gene
81 knockouts and overexpression of proteases^{15,33,34}.

82 To explore proteolytic degradation under antibiotic stress, we have applied queueing theory to
83 affect protein degradation. Previous studies have used knockout mutants to affect protease activity,
84 but these studies yielded mixed and conflicting results^{6,21,23,35-37}. The variability between results of
85 knockout mutations could be due to differences in growth rates, which would modulate antibiotic
86 efficacy. Proteolytic queueing is preferred over protease knockouts when probing antibiotic
87 efficacy because protease knockouts often result in growth defects^{15,33}, but proteolytic queueing
88 does not noticeably affect cell growth or death^{28-30,32}, even in stationary phase (Fig. S1). Our results
89 show that during antibiotic treatment, degradation plays a role in cell survival and the effect is

90 tunable using queue formation. Proteolytic queueing at ClpXP increases antibiotic survival and
91 analysis of population decay with and without a queue demonstrates that queueing specifically
92 increases antibiotic tolerance. Indeed, the results we describe here would not have been identified
93 in a *clpP* knockout; *clpP* knockouts have growth defects³⁴ and any increase in tolerance would
94 have been difficult to differentiate from this effect. We hypothesize that the queue is affecting the
95 degradation of one or many regulatory molecules within the cell that cause downstream effects
96 and enhance antibiotic tolerance. These results demonstrate that proteolytic queueing provides a
97 new method to probe antibiotic tolerance and persistence.

98 *Proteolytic queueing affects tolerance*

99 We used *E. coli* strains derived from DH5 α Z1³² (a common strain used in synthetic biology) to
100 test antibiotic tolerance and persistence. Cultures were grown to stationary phase and incubated
101 for 24 hours prior to dilution into fresh media containing ampicillin to quantify persistence (see
102 Methods). A proteolytic queue was induced via the production of a tagged fluorescent protein,
103 CFP-LAA, which we expressed under an IPTG inducible promoter, P_{lac/ara-1}. This synthetic strain
104 has previously been used to study proteolytic queueing³², and other queueing studies have used
105 similar constructs^{28-30,38}. No apparent change in growth was observed by induction (Fig. S1) as
106 reported previously^{29,30}. The effects of queue formation on antibiotic survival are shown as the
107 percentage of the population that survived ampicillin treatment (Fig 2). When CFP alone (the no
108 degradation tag control) was overexpressed during ampicillin treatment, there was no significant
109 effect on persister levels ($p > 0.2$, Fig. 2A). Queue formation (overexpression of CFP-LAA) during
110 ampicillin treatment led to a 25-fold increase in survival after three hours in a concentration-
111 dependent manner (Fig. 2B; $p < 0.0001$, $n \geq 12$).

112 When a queue was induced for 24 hours prior to ampicillin treatment the surviving population
113 was over 80-fold higher than the uninduced population, only if induction was maintained during
114 ampicillin treatment. However, if the inducer was removed during ampicillin treatment, the initial
115 24 hours of queueing had a minimal effect on survival after three hours ($p > 0.01$, Fig. 2C). These
116 results indicate that survival was affected by queue formation rather than CFP itself, and that the
117 size of the queue (level and length of induction) determines the level of the effect. To confirm that
118 these results are due to induction during antibiotic treatment, we waited one hour into ampicillin
119 treatment before inducing expression of the fluorescent protein. As we previously observed,
120 induction of untagged CFP had no apparent effect on persister levels (Fig. 2D). Quantification of
121 fluorescence after ampicillin treatment confirmed that CFP was produced (Fig. 2E), and
122 overexpression of CFP-LAA for two hours of ampicillin treatment still increased cell survival
123 compared to the uninduced and untagged CFP populations (Fig. 2D).

124 We did further testing to confirm this effect is not specific to glycerol as a carbon source or
125 ampicillin as the antibiotic. When glucose was the carbon source rather than glycerol, survival still
126 increased due to CFP-LAA induction (Fig. 2F), which demonstrates that the effect is not directly
127 related to the carbon source. We then tested the effects of queueing against the antibiotic
128 ciprofloxacin, because ciprofloxacin targets DNA gyrase³⁹ while ampicillin targets the cell wall⁴⁰.
129 CFP alone caused an increase in survival (Fig. 3A), but the CFP-LAA tag led to a vastly higher
130 number of persisters. We suspect that high production of CFP with no apparent method of removal
131 (besides cell division; minimal degradation) could cause cell stress and affect survival, especially
132 since high levels of fluorescent proteins can cause oxidative stress^{41,42}, which is known to increase
133 persistence⁴³⁻⁴⁵. However, CFP-LAA is removed via degradation (indicated by lower fluorescence
134 than CFP-untagged), and thus the effects seen via overexpression of CFP should be less prominent

135 during CFP-LAA overexpression. In fact, queue induction increased survival during ciprofloxacin
136 treatment approximately 60-fold (Fig. 3B). These results indicate that the effects of CFP-LAA can
137 be largely attributed to queueing rather than overexpression of CFP itself and demonstrate that
138 queueing effects on antibiotic survival are observed for two carbon sources and two different types
139 of antibiotics.

140 *Chloramphenicol inhibits the synthetic queue*

141 Neither ampicillin nor ciprofloxacin directly affect production of the fluorescent protein (i.e.
142 target transcription or translation) and thus should not prevent queue formation. On the other hand,
143 an antibiotic that affects protein production should prevent queue formation, and therefore CFP-
144 LAA induction would not affect survival in the presence of such an antibiotic. We found this to be
145 the case when testing the effects of queueing on the survival of cells treated with chloramphenicol.
146 Chloramphenicol is an antibiotic that inhibits protein translation by binding to bacterial ribosomes
147 and inhibiting protein synthesis, thereby inhibiting bacterial growth⁴⁶. Induction of CFP-LAA does
148 not increase survival of antibiotic treatment when treated with chloramphenicol alone (Fig. S2),
149 but chloramphenicol is not bactericidal, so we also co-treated cultures with ampicillin and
150 chloramphenicol. The overall percent survival with chloramphenicol is much higher than with
151 ampicillin alone, which is consistent with the literature⁴⁷. As expected, co-treatment with
152 ampicillin and chloramphenicol had no apparent effect on cell survival, supporting that even when
153 CFP-LAA was induced the queue could not form if translation was blocked (Fig. 3C).

154 *Proteolytic queueing affects population decay*

155 To gain further insight into the relationship between proteolytic queueing, tolerance and
156 persistence, we measured how a proteolytic queue affects population decay by measuring survival
157 for up to 8 hours of ampicillin treatment. Our results show a typical biphasic curve indicative of

158 persister cells in the uninduced population. When the population is induced 24 hours prior to and
159 during antibiotic treatment this curve shifts as the rate of population decay slows compared to
160 uninduced cultures. The addition of the inducer solely during antibiotic treatment has a similar
161 effect between two and three hours into treatment. If the queue is induced 24 hours prior to
162 antibiotic treatment, but the queue is not maintained (i.e. the inducer is removed during antibiotic
163 treatment) the effect of the queue dissipates between one to two hours. There is no apparent
164 difference between induced and uninduced cultures after 8 hours, which suggests there is little to
165 no effect on persistence (Fig. 4A). In some cases, the change in survival at three hours might be
166 interpreted as a change in persistence; however, the shift in decay rates (as described in Fig. 1A)
167 clearly demonstrates that queueing increases antibiotic tolerance rather than persistence.
168 Furthermore, the effects caused by adding or removing the inducer during antibiotic treatment
169 suggest that the change in antibiotic tolerance is due to an active response to the queue, which
170 must be maintained to affect survival.

171 *Computational modeling of tolerance/persistence*

172 Based on the *in vivo* results, we considered a computational model of population decay during
173 antibiotic treatment modified from Kussel *et al.*⁴⁸. While it is difficult to differentiate between
174 persisters and tolerant cells experimentally, the model allows us to explore how the distribution of
175 persistence and tolerance within a population affects population decay. In our model, the persister
176 population (P) has a lower death rate than the susceptible population (N), where the death rates are
177 represented by μ_p and μ_n respectively. We estimated μ_p and μ_n based on the decay rate of the
178 uninduced population before and after two hours, and set the initial persister population to 0.2%
179 of the total population (Fig. 4B). Normal (susceptible) cells enter persistence at rate α , and persister
180 cells return to the normal state at rate β . The rates α and β were set relative to μ_n based on the

181 relationship between these values in Kussel *et al*⁴⁸. Our base model closely resembles population
182 decay as measured in experimental tests. We use the model to determine whether the increase in
183 overall population survival due to queue formation can be attributed to an increased rate of entering
184 persistence (α) or increased tolerance (i.e. decreased μ_n). Exploration of these parameters using
185 stochastic simulations shows that increasing the rate at which normal cells become persisters (α)
186 does not affect the length of the first phase of population decay (Fig. 4C), while decreasing the
187 rate of normal cell death (μ_n) lengthens the first phase of population decay (Fig. 4D). Thus, our
188 model supports that the effect of queueing on population decay is due to an increase in antibiotic
189 tolerance.

190 *Discussion*

191 Proteolytic queueing is an integral component of native systems that has great potential for
192 applications outside of synthetic biology. Here we show that queueing provides a tunable method
193 to interfere with protease degradation and affect antibiotic tolerance. Although persistence does
194 not appear to be affected by the proteolytic queue at ClpXP, the effect may simply need to be
195 stronger than what we tested here, or perhaps slowed translation and transcription of persister cells
196 may be preventing induction of the queue during the persister state. An increase in antibiotic
197 tolerance due to queue formation may be specific to overexpression of the LAA-tag, especially
198 when considering that the number of LAA tagged proteins in a native system increases during
199 stress. For example, the number of proteins with LAA tags increase during heat shock⁴⁹, and queue
200 formation at the proteases is likely a consequence of the increasing cellular traffic. Furthermore,
201 removing the LAA tag from SsrA while maintaining the ribosome rescue function results in a
202 decreased survival of ampicillin treatment in *E. coli*²¹. As the LAA tag could be a measurement of
203 environmental stress, cells may have evolved to increase tolerance in response to increased

204 queueing via LAA. As such, the effects of proteolytic queueing could be common to prokaryotes
205 when considering the role of the ribosome rescue system during stress.

206 Proteolytic queueing is likely also affecting the proteome of the cell, either directly or indirectly.
207 Pleiotropic effects on protein content and gene regulation could be limiting antibiotic efficacy.
208 Queue formation likely increases the intracellular concentration of multiple protein species causing
209 a regulatory cascade. When considering proteins both degraded by ClpXP and related to
210 persistence, TA systems are unlikely to be the causative factor, because decreasing degradation
211 should increase antitoxin levels and decrease survival rather than increase survival as we observe.
212 Regulatory proteins are possible candidates for the causative factor in queueing effects on
213 tolerance. Such proteins include RpoS and DksA (both degraded by ClpXP), which have been
214 implicated in persistence^{21,45,50} and may be involved in tolerance. Increased concentrations of these
215 regulatory proteins due to slowed degradation could be causing downstream effects that lead to
216 increased tolerance. In a similar vein, computational modeling has shown that altering degradation
217 of MarA (a regulatory protein related to antibiotic tolerance) leads to increased coordination of
218 downstream genes⁵¹. While these results are specific to queueing at ClpXP, tags are available to
219 test the effects of queueing at other proteases (e.g. Lon and ClpAP)³². Because proteolytic
220 regulation of gene regulatory proteins is common throughout prokaryotes, identifying which
221 proteins are affected by queueing could provide key details concerning the cellular mechanisms of
222 antibiotic tolerance.

223 *Conclusion*

224 We have found that the level of antibiotic tolerance increases upon induction of a proteolytic
225 queue at ClpXP via overexpression of LAA tagged proteins. The effect of queueing on cell survival
226 of ampicillin and ciprofloxacin relies on queue induction during antibiotic treatment, and therefore

227 transcription and translation must be occurring during antibiotic treatment to maintain the queue.
228 While it is unlikely that TA systems are responsible for the increase in survival due to queue
229 formation, there could be one or many regulatory proteins perturbed by the queue that affect
230 tolerance. It is probable that cells have evolved to increase antibiotic tolerance in response to
231 environmental stress, which may be signaled by proteolytic queues. Alternatively, the
232 phenomenon could be a specific response to an overabundance of LAA tagged proteins, which
233 would naturally occur during nutrient starvation because of increased ribosome stalling.
234 Identifying regulatory proteins of bacterial tolerance and persistence and understanding how these
235 proteins interact with the whole cell are of great interest because they provide potential targets for
236 killing bacterial pathogens, and proteolytic queues are a new method to explore these regulatory
237 elements.

238 **Materials and Methods**

239 *Strains and Plasmids*

240 All strains are derived from *E. coli* DH5 α Z1, and contain plasmids with the synthetic circuits,
241 p24KmNB82 (CFP-LAA) and p24KmNB83 (untagged CFP) as described in REF³². The cultures
242 were grown in modified MMA media⁵², which we will refer to as MMB. MMB media consists of
243 the following: K₂HPO₄ (10.5 mg/ml), KH₂PO₄ (4.5 mg/ml), (NH₄)₂SO₄ (2.0 mg/ml), C₆H₅Na₃O₇
244 (0.5 mg/ml) and NaCl (1.0 mg/ml). Additionally, MMB+ consists of MMB and the following: 2
245 mM MgSO₄ x 7H₂O, 100 μ M CaCl₂, thiamine (10 μ g/ml), 0.5% glycerol and amino acids (40
246 μ g/ml). Cultures grown on glucose as the carbon source included 0.5% glucose instead of glycerol.
247 Strains containing the plasmid p24Km and derivatives were grown in MMB+ kanamycin (Km, 25
248 μ g/ml) or on Miller's Lysogeny broth (LB) agar plates + Km (25 μ g/ml). All cultures were
249 incubated at 37°C and broth cultures were shaken at 250 rpm.

250 *Quantification of persistence*

251 Persisters were quantified by comparing colony-forming units per milliliter (CFU/ml) before
252 antibiotic treatment to CFU/ml after antibiotic treatment. The procedure for quantifying persister
253 levels is based on previous research⁵³⁻⁵⁵ (Fig. S3). Briefly, overnight cultures were diluted 1/100
254 into fresh media and grown until they reach approximately OD₆₀₀ 0.3. A reduced volume of culture
255 (20 ml) was aliquoted into a 125 ml flask, and grown for 16 hours to enter stationary phase. Once
256 in stationary phase, cultures were divided into two flasks with 0.2% arabinose, one flask of each
257 replicate was also treated with 100 nM IPTG to induce expression under P_{lac/ara-1}. Arabinose was
258 added to both induced and uninduced cultures to maintain consistency (Fig. S4). All flasks were
259 incubated for 24 hours before taking samples for plating and antibiotic treatment; cells were diluted
260 1/100^{53,54} into glass tubes, treated with 10X the MIC of ampicillin (100 µg/ml; Fig. S5) or 100X
261 MIC of ciprofloxacin (1 µg/ml) at 37°C and shaken at 250 rpm for select time periods, 3 hours
262 unless otherwise stated. Ampicillin solutions were stored at -80°C and only thawed once to reduce
263 variability^{19,56}. When indicated, samples were treated with chloramphenicol (5 µg/ml); cultures
264 treated with chloramphenicol alone were diluted 1/10. Samples for quantification of CFU/ml were
265 kept on ice and diluted using cold MMB before plating on LB/Km (25 µg/ml) agar plates. Cultures
266 treated with ciprofloxacin were centrifuged at 16,000 *x g* for 3 minutes then washed with cold
267 MMB to dilute ciprofloxacin before taking samples for quantification. LB agar plates were
268 incubated at 37°C for 40-48 hours, then scanned using a flatbed scanner^{57,58}. Custom scripts were
269 used to identify and count bacterial colonies⁵⁹ then calculate CFU/ml and persister frequency.
270 Colonies were tested periodically for resistance, and we found no resistance in >350 colonies
271 tested.

272 *Quantification of CFP*

273 Cells were grown and treated with ampicillin as described for quantification of persistence
274 above. After antibiotic treatment, 300 μ l of cell culture was added to individual wells in a 96-Well
275 Optical-Bottom Plate with Polymer Base (ThermoFisher) for fluorescence measurement using
276 FLUOstar Omega microplate reader. The excitation and emission (Ex/Em) used for CFP
277 measurement was 440/480. Readings were measured after four minutes of shaking to decrease
278 variability between wells. Background fluorescence (mean fluorescence of MMB media) was
279 subtracted from the raw reads. Fluorescence values were normalized by CFUs as determined by
280 quantification of persistence, which was carried out simultaneously. Mean and SEM for
281 fluorescence was determined across four biological replicates and three technical replicates.

282 *Computational modeling*

283 Our model is modified from Kussel *et al.*⁴⁸ where P is the persister population and N is the total
284 population (Fig 4B). Initial species counts P and N were set to 9998 and 2 respectively for all
285 simulations, which we based on the percent survival of uninduced cultures. The death rate of N
286 (μ_n) and P (μ_p) and the rate of entering (α) and exiting (β) persistence were set as shown in Fig. 4B
287 unless otherwise stated. The rate of normal cell division (ω) was set to zero, as normal cells cannot
288 divide without lysis during ampicillin treatment⁶⁰. All simulations were performed using a custom
289 implementation of the Gillespie algorithm⁶¹ in Python leveraging optimizations made possible by
290 the Cython library⁶². Libraries from the SciPy stack⁶³ were used for analysis.

291 *Statistics*

292 All data is presented as mean \pm SD or SEM of at least 3 biological replicates as appropriate⁶⁴.
293 Statistical significance for populations with the same number of replicates (n) was determined
294 using one-way f-test to determine variance ($p < 0.001$ was considered to have significant variance)

295 followed by a Student's t-test (no variance) or a Welch's t-test (significant variance). Populations
296 with different n values were compared using a Welch's t-test. All statistical tests were run in
297 Python using libraries from SciPy on groups with at least three biological replicates.

298 *Data availability*

299 The data that supports the findings of this study are available from the corresponding author upon
300 reasonable request.

301 *Code availability*

302 Code used for model simulations is available on GitHub at
303 https://github.com/ctogle/mini_gillespiem. Code used for colony counting is available on GitHub
304 at <https://github.com/hdeter/CountColonies>.

305 **Acknowledgments**

306 This work is supported by the Hatch project grant no. SD00H653-18/project accession no.
307 1015687 from the USDA National Institute of Food and Agriculture.

308 **Author contributions**


309 H.S.D wrote the manuscript, developed custom code for colony counting, and ran statistical
310 analyses. A.A. performed ampicillin and ciprofloxacin persister assays. P.J. performed plate reader
311 assays. E.S. performed chloramphenicol persister assay. C.T.O. and H.S.D. adapted the persister
312 model and ran stochastic simulations. N.C.B. initiated and directed the project. All authors
313 contributed to discussing and editing the manuscript.

314 **Competing interests**

315 The authors declare no competing interests.


316 **Correspondence and request for materials** should be addressed to N.C.B.

317 **Figures**




318

319 **Fig 1. a**, Examples of population decay in typical (black), high persistence (blue) and high
320 tolerance (red) populations. A shift in tolerance can be distinguished from a change in the number
321 of persisters. For example, a high persistence population can initially have the same decay rate as
322 a typical population, but have higher survival because of more persisters (dotted blue line). A high
323 tolerance population can have the same persister level as a typical population, but have a shift in
324 the initial decay rate (dotted red line). **b**, A simple model of proteolytic queueing. When native
325 proteins have low competition for the protease, there is no queue. Induction of synthetic tagged
326 proteins competes with the native proteins for the protease and overloads the protease, which
327 results in a proteolytic queue (bottleneck).



328


329 **Fig. 2. Proteolytic queueing affects survival of cells treated with the antibiotic ampicillin.**
 330 Induction of untagged CFP during antibiotic treatment has no significant effect on survival ($p > 0.2$).
 331 **b**, Induction of CFP-LAA during antibiotic treatment causes an increase in persistence. **c**, CFP-
 332 LAA was induced (+) with 100 μM of IPTG or not induced (-). Induction before ampicillin lasted
 333 24 h in stationary phase prior to antibiotic treatment. Queueing only affects survival if the queue
 334 is maintained during ampicillin treatment. **d-e**, Expression of CFP or CFP-LAA was induced with
 335 IPTG one hour into the three-hour antibiotic treatment. Induction of CFP alone (no queue) had no
 336 significant effects on survival. Induction of CFP-LAA increased survival (**d**). Population
 337 fluorescence was measured for untagged CFP after antibiotic treatment, demonstrating that CFP
 338 is being produced via induction (**e**). **f**, Induction of CFP-LAA during antibiotic treatment causes
 339 an increase in persistence with glucose as a carbon source rather than glycerol, demonstrating that
 340 it is not a solely a carbon-specific phenomenon. Error bars represent SEM. $n \geq 3$. * $p < 0.05$.
 341 ** $p < 0.01$. *** $p < 0.001$. **** $p < 0.0001$.




342

343 **Fig. 3. Proteolytic queueing effects in the presence of ciprofloxacin and chloramphenicol. a,**
344 Induction of untagged CFP during ciprofloxacin treatment increases survival less than 4-fold. **b,**
345 Induction of CFP-LAA during ciprofloxacin treatment increases survival over 50-fold. **c,** Induction
346 of CFP-LAA during ampicillin and chloramphenicol treatment has no apparent effect on
347 persistence ($p > 0.7$). X-axis labels correspond to Fig. 2. Error bars represent SEM. $n \geq 3$. * $p < 0.05$.
348 ** $p < 0.01$.

349 **Fig. 4. Time of queue formation influences**
 350 **survival. a**, Stationary phase cells were
 351 diluted 1/100 into fresh media containing
 352 ampicillin (100 $\mu\text{g/ml}$) and sampled every
 353 hour for 8 h ($n \geq 3$). Symbols (-/+) correspond
 354 to Fig. 2C. Error bars represent SEM.
 355 Asterisks indicate p-value (compared to no
 356 induction (black)) * $p < 0.05$, ** $p < 0.01$,
 357 *** $p < 0.001$, **** $p < 0.0001$. There is 100%
 358 survival at time zero, because percent
 359 survival is determined based on the surviving
 360 CFU/ml compared to the CFU/ml at time
 361 zero. **b-d**, Stochastic model of population
 362 decay with antibiotic treatment. **b**, Reactions
 363 for the model (left) and baseline reaction rates
 364 used for the simulations (right) unless stated
 365 otherwise (red lines below). Normal cell
 366 division (ω) was set to zero as dividing cells
 367 die during ampicillin treatment. **c**, Increasing
 368 the rate of entering persistence (α) increases
 369 cell number during the second phase of
 370 population decay. Inset is indicated by the
 371 dotted black line. **d**, Decreasing the rate of
 372 normal cell death (μ_n) causes the first phase
 373 of population decay to lengthen.




374 Supplementary Figures and Data




375

376 **Fig S1. Induction of untagged CFP and CFP-LAA tag has no apparent effect on growth in**
377 **MMB+ media.** The Y-axis is in log CFU/ml of induced and uninduced cultures over 48 hours.
378 $n \geq 3$. Error bars represent the standard deviation.




379

380 **Fig. S2. Induction of CFP-LAA does not increase survival of cells treated with**
381 **chloramphenicol.** Cultures were treated with chloramphenicol, an antibiotic that inhibits
382 translation, after a 1/10 dilution into fresh media from stationary phase. Induction of CFP-LAA
383 via IPTG had no significant change in persistence compared to the uninduced cultures ($p > 0.7$;
384 $n \geq 3$). Error bars represent SEM.




385

386 **Fig. S3. Persister assay flow chart.** See Methods for details.



387

388 **Fig. S4. The addition of arabinose had no apparent effect on the tolerance/persister level**
389 **during ampicillin treatment.** Both IPTG and arabinose are inducers for CFP untagged and CFP-
390 LAA tagged proteins. IPTG induces expression, arabinose alone does not induce expression, but
391 arabinose can enhance expression when used in combination with IPTG. The effect of adding
392 arabinose (0.2%) on tolerance/persistence to ampicillin was tested with CFP-LAA. Adding
393 arabinose does not have a significant effect on survival of cells after 3 hours of ampicillin treatment
394 ($p > 0.3$). Error bars represent SEM. $n \geq 3$.



395

396 **Fig S5. Determination of Minimal Inhibitory Concentration (MIC) for ampicillin.**

397 Exponential phase cultures were treated with different concentrations of ampicillin. The MIC was

398 determined to be 10 μg/ml ($p < 0.03$ compared to zero). Error bars represent the standard deviation.

399 **References**

- 400 1 Baker, S., Thomson, N., Weill, F. X. & Holt, K. E. Genomic insights into the emergence
401 and spread of antimicrobial-resistant bacterial pathogens. *Science* **360**, 733-738,
402 doi:10.1126/science.aar3777 (2018).
- 403 2 Durao, P., Balbontin, R. & Gordo, I. Evolutionary Mechanisms Shaping the Maintenance
404 of Antibiotic Resistance. *Trends Microbiol*, doi:10.1016/j.tim.2018.01.005 (2018).
- 405 3 Michiels, J. E., Van den Bergh, B., Verstraeten, N. & Michiels, J. Molecular mechanisms
406 and clinical implications of bacterial persistence. *Drug Resist Updat* **29**, 76-89,
407 doi:10.1016/j.drug.2016.10.002 (2016).
- 408 4 Fisher, R. A., Gollan, B. & Helaine, S. Persistent bacterial infections and persister cells.
409 *Nat Rev Microbiol* **15**, 453-464, doi:10.1038/nrmicro.2017.42 (2017).
- 410 5 Balaban, N. Q. *et al.* Definitions and guidelines for research on antibiotic persistence.
411 *Nat Rev Microbiol*, doi:10.1038/s41579-019-0196-3 (2019).
- 412 6 Kim, J. S. & Wood, T. K. Persistent Persister Misperceptions. *Front Microbiol* **7**, 2134,
413 doi:10.3389/fmicb.2016.02134 (2016).
- 414 7 Moll, I. & Engelberg-Kulka, H. Selective translation during stress in *Escherichia coli*.
415 *Trends in biochemical sciences* **37**, 493-498, doi:10.1016/j.tibs.2012.07.007 (2012).
- 416 8 Soo, V. W., Cheng, H. Y., Kwan, B. W. & Wood, T. K. de novo synthesis of a bacterial
417 toxin/antitoxin system. *Sci Rep* **4**, 4807, doi:10.1038/srep04807 (2014).
- 418 9 Ronneau, S. & Helaine, S. Clarifying the Link between Toxin-Antitoxin Modules and
419 Bacterial Persistence. *Journal of Molecular Biology*, doi:10.1016/j.jmb.2019.03.019
420 (2019).
- 421 10 Deter, H. S., Jensen, R. V., Mather, W. H. & Butzin, N. C. Mechanisms for Differential
422 Protein Production in Toxin-Antitoxin Systems. *Toxins (Basel)* **9**,
423 doi:10.3390/toxins9070211 (2017).
- 424 11 Overgaard, M., Borch, J., Jorgensen, M. G. & Gerdes, K. Messenger RNA interferase
425 RelE controls *relBE* transcription by conditional cooperativity. *Mol Microbiol* **69**, 841-857,
426 doi:10.1111/j.1365-2958.2008.06313.x (2008).
- 427 12 Kasari, V., Mets, T., Tenson, T. & Kaldalu, N. Transcriptional cross-activation between
428 toxin-antitoxin systems of *Escherichia coli*. *BMC Microbiol* **13**, 45, doi:10.1186/1471-
429 2180-13-45 (2013).
- 430 13 Muthuramalingam, M., White, J. C. & Bourne, C. R. Toxin-Antitoxin Modules Are Pliable
431 Switches Activated by Multiple Protease Pathways. *Toxins (Basel)* **8**,
432 doi:10.3390/toxins8070214 (2016).
- 433 14 Janssen, B. D., Garza-Sanchez, F. & Hayes, C. S. YoeB toxin is activated during
434 thermal stress. *Microbiologyopen* **4**, 682-697, doi:10.1002/mbo3.272 (2015).
- 435 15 Gottesman, S. Proteases and their targets in *Escherichia coli*. *Annu Rev Genet* **30**, 465-
436 506, doi:10.1146/annurev.genet.30.1.465 (1996).
- 437 16 Baker, T. A. & Sauer, R. T. ClpXP, an ATP-powered unfolding and protein-degradation
438 machine. *Biochim Biophys Acta* **1823**, 15-28, doi:10.1016/j.bbamcr.2011.06.007 (2012).
- 439 17 Ranquet, C. & Gottesman, S. Translational regulation of the *Escherichia coli* stress
440 factor RpoS: a role for SsrA and Lon. *J Bacteriol* **189**, 4872-4879, doi:10.1128/JB.01838-
441 06 (2007).
- 442 18 Janssen, B. D. & Hayes, C. S. The tmRNA ribosome-rescue system. *Adv Protein Chem*
443 *Struct Biol* **86**, 151-191, doi:10.1016/B978-0-12-386497-0.00005-0 (2012).
- 444 19 Luidalepp, H., Hallier, M., Felden, B. & Tenson, T. tmRNA decreases the bactericidal
445 activity of aminoglycosides and the susceptibility to inhibitors of cell wall synthesis. *RNA*
446 *Biol* **2**, 70-74, doi:10.4161/rna.2.2.2020 (2005).
- 447 20 Liu, S. *et al.* Variable Persister Gene Interactions with (p)ppGpp for Persister Formation
448 in *Escherichia coli*. *Front Microbiol* **8**, 1795, doi:10.3389/fmicb.2017.01795 (2017).

- 449 21 Amato, S. M. & Brynildsen, M. P. Persister Heterogeneity Arising from a Single
450 Metabolic Stress. *Curr Biol* **25**, 2090-2098, doi:10.1016/j.cub.2015.06.034 (2015).
- 451 22 Wang, W. *et al.* Transposon Mutagenesis Identifies Novel Genes Associated with
452 *Staphylococcus aureus* Persister Formation. *Front Microbiol* **6**, 1437,
453 doi:10.3389/fmicb.2015.01437 (2015).
- 454 23 Wu, N. *et al.* Ranking of persister genes in the same *Escherichia coli* genetic
455 background demonstrates varying importance of individual persister genes in tolerance
456 to different antibiotics. *Front Microbiol* **6**, 1003, doi:10.3389/fmicb.2015.01003 (2015).
- 457 24 Wu, S., Yu, P. L., Wheeler, D. & Flint, S. Transcriptomic study on persistence and
458 survival of *Listeria monocytogenes* following lethal treatment with nisin. *J Glob*
459 *Antimicrob Resist* **15**, 25-31, doi:10.1016/j.jgar.2018.06.003 (2018).
- 460 25 Conlon, B. P. *et al.* Activated ClpP kills persisters and eradicates a chronic biofilm
461 infection. *Nature* **503**, 365-370, doi:10.1038/nature12790 (2013).
- 462 26 Butzin, N. C. & Mather, W. H. Synthetic genetic oscillators. *Reviews in Cell Biology and*
463 *Molecular Medicine* (2015).
- 464 27 Stricker, J. *et al.* A fast, robust and tunable synthetic gene oscillator. *Nature* **456**, 516-
465 519, doi:10.1038/nature07389 (2008).
- 466 28 Cookson, N. A. *et al.* Queueing up for enzymatic processing: correlated signaling
467 through coupled degradation. *Mol Syst Biol* **7**, 561, doi:10.1038/msb.2011.94 (2011).
- 468 29 Butzin, N. C., Hochendoner, P., Ogle, C. T. & Mather, W. H. Entrainment of a Bacterial
469 Synthetic Gene Oscillator through Proteolytic Queueing. *ACS Synth Biol* **6**, 455-462,
470 doi:10.1021/acssynbio.6b00157 (2017).
- 471 30 Butzin, N. C., Hochendoner, P., Ogle, C. T., Hill, P. & Mather, W. H. Marching along to
472 an Offbeat Drum: Entrainment of Synthetic Gene Oscillators by a Noisy Stimulus. *ACS*
473 *Synth Biol* **5**, 146-153, doi:10.1021/acssynbio.5b00127 (2016).
- 474 31 Mather, W. H., Cookson, N. A., Hasty, J., Tsimring, L. S. & Williams, R. J. Correlation
475 resonance generated by coupled enzymatic processing. *Biophys J* **99**, 3172-3181,
476 doi:10.1016/j.bpj.2010.09.057 (2010).
- 477 32 Butzin, N. C. & Mather, W. H. Crosstalk between Diverse Synthetic Protein Degradation
478 Tags in *Escherichia coli*. *ACS Synth Biol* **7**, 54-62, doi:10.1021/acssynbio.7b00122
479 (2018).
- 480 33 Thomsen, L. E., Olsen, J. E., Foster, J. W. & Ingmer, H. ClpP is involved in the stress
481 response and degradation of misfolded proteins in *Salmonella enterica* serovar
482 Typhimurium. *Microbiology* **148**, 2727-2733, doi:10.1099/00221287-148-9-2727 (2002).
- 483 34 Weichart, D., Querfurth, N., Dreger, M. & Hengge-Aronis, R. Global role for ClpP-
484 containing proteases in stationary-phase adaptation of *Escherichia coli*. *J Bacteriol* **185**,
485 115-125, doi:10.1128/jb.185.1.115-125.2003 (2003).
- 486 35 Springer, M. T., Singh, V. K., Cheung, A. L., Donegan, N. P. & Chamberlain, N. R. Effect
487 of clpP and clpC deletion on persister cell number in *Staphylococcus aureus*. *J Med*
488 *Microbiol* **65**, 848-857, doi:10.1099/jmm.0.000304 (2016).
- 489 36 Harms, A., Fino, C., Sorensen, M. A., Semsey, S. & Gerdes, K. Prophages and Growth
490 Dynamics Confound Experimental Results with Antibiotic-Tolerant Persister Cells. *MBio*
491 **8**, doi:10.1128/mBio.01964-17 (2017).
- 492 37 Shan, Y. *et al.* ATP-Dependent Persister Formation in *Escherichia coli*. *MBio* **8**,
493 doi:10.1128/mBio.02267-16 (2017).
- 494 38 Prindle, A. *et al.* Rapid and tunable post-translational coupling of genetic circuits. *Nature*
495 **508**, 387-391, doi:10.1038/nature13238 (2014).
- 496 39 Hooper, D. C., Wolfson, J. S., Ng, E. Y. & Swartz, M. N. Mechanisms of action of and
497 resistance to ciprofloxacin. *Am J Med* **82**, 12-20 (1987).
- 498 40 Kohanski, M. A., Dwyer, D. J. & Collins, J. J. How antibiotics kill bacteria: from targets to
499 networks. *Nat Rev Microbiol* **8**, 423-435, doi:10.1038/nrmicro2333 (2010).

- 500 41 Ganini, D. *et al.* Fluorescent proteins such as eGFP lead to catalytic oxidative stress in
501 cells. *Redox Biol* **12**, 462-468, doi:10.1016/j.redox.2017.03.002 (2017).
- 502 42 Kalyanaraman, B. & Zielonka, J. Green fluorescent proteins induce oxidative stress in
503 cells: A worrisome new wrinkle in the application of the GFP reporter system to
504 biological systems? *Redox Biol* **12**, 755-757, doi:10.1016/j.redox.2017.03.019 (2017).
- 505 43 Cohen, N. R., Lobritz, M. A. & Collins, J. J. Microbial persistence and the road to drug
506 resistance. *Cell Host Microbe* **13**, 632-642, doi:10.1016/j.chom.2013.05.009 (2013).
- 507 44 Wang, T., El Meouche, I. & Dunlop, M. J. Bacterial persistence induced by salicylate via
508 reactive oxygen species. *Sci Rep* **7**, 43839, doi:10.1038/srep43839 (2017).
- 509 45 Trastoy, R. *et al.* Mechanisms of Bacterial Tolerance and Persistence in the
510 Gastrointestinal and Respiratory Environments. *Clin Microbiol Rev* **31**,
511 doi:10.1128/CMR.00023-18 (2018).
- 512 46 Hong, W., Zeng, J. & Xie, J. Antibiotic drugs targeting bacterial RNAs. *Acta Pharm Sin B*
513 **4**, 258-265, doi:10.1016/j.apsb.2014.06.012 (2014).
- 514 47 Kwan, B. W., Valenta, J. A., Benedik, M. J. & Wood, T. K. Arrested protein synthesis
515 increases persister-like cell formation. *Antimicrob Agents Chemother* **57**, 1468-1473,
516 doi:10.1128/AAC.02135-12 (2013).
- 517 48 Kussell, E., Kishony, R., Balaban, N. Q. & Leibler, S. Bacterial persistence: a model of
518 survival in changing environments. *Genetics* **169**, 1807-1814,
519 doi:10.1534/genetics.104.035352 (2005).
- 520 49 Morgan, G. J., Burkhardt, D. H., Kelly, J. W. & Powers, E. T. Translation efficiency is
521 maintained at elevated temperature in *Escherichia coli*. *J Biol Chem* **293**, 777-793,
522 doi:10.1074/jbc.RA117.000284 (2018).
- 523 50 Radzikowski, J. L. *et al.* Bacterial persistence is an active sigmaS stress response to
524 metabolic flux limitation. *Mol Syst Biol* **12**, 882, doi:10.15252/msb.20166998 (2016).
- 525 51 Rossi, N. A., Mora, T., Walczak, A. M. & Dunlop, M. J. Active degradation of MarA
526 controls coordination of its downstream targets. *PLoS Comput Biol* **14**, e1006634,
527 doi:10.1371/journal.pcbi.1006634 (2018).
- 528 52 Miller, J. H. *Experiments in molecular genetics*. (Cold Spring Harbor Laboratory, 1972).
- 529 53 Joers, A., Kaldalu, N. & Tenson, T. The frequency of persisters in *Escherichia coli*
530 reflects the kinetics of awakening from dormancy. *J Bacteriol* **192**, 3379-3384,
531 doi:10.1128/JB.00056-10 (2010).
- 532 54 Gefen, O., Gabay, C., Mumcuoglu, M., Engel, G. & Balaban, N. Q. Single-cell protein
533 induction dynamics reveals a period of vulnerability to antibiotics in persister bacteria.
534 *Proc Natl Acad Sci U S A* **105**, 6145-6149, doi:10.1073/pnas.0711712105 (2008).
- 535 55 Rowe, S. E., Conlon, B. P., Keren, I. & Lewis, K. Persisters: Methods for Isolation and
536 Identifying Contributing Factors--A Review. *Methods Mol Biol* **1333**, 17-28,
537 doi:10.1007/978-1-4939-2854-5_2 (2016).
- 538 56 Nickolai, D. J. *et al.* Effects of storage temperature and pH on the stability of eleven
539 beta-lactam antibiotics in MIC trays. *J Clin Microbiol* **21**, 366-370 (1985).
- 540 57 Levin-Reisman, I. *et al.* Antibiotic tolerance facilitates the evolution of resistance.
541 *Science* **355**, 826-830, doi:10.1126/science.aaj2191 (2017).
- 542 58 Datla, U. S. *et al.* The spatiotemporal system dynamics of acquired resistance in an
543 engineered microecology. *Sci Rep* **7**, 16071, doi:10.1038/s41598-017-16176-w (2017).
- 544 59 Deter, H. S., Dies, M., Cameron, C. C., Butzin, N. C. & Buceta, J. in *Computer*
545 *Optimized Microscopy: Methods and Protocols* (Springer's Methods in Molecular
546 Biology, 2019. In Press.).
- 547 60 Balaban, N. Q., Merrin, J., Chait, R., Kowalik, L. & Leibler, S. Bacterial persistence as a
548 phenotypic switch. *Science* **305**, 1622-1625, doi:10.1126/science.1099390 (2004).
- 549 61 Gillespie, D. T. Exact stochastic simulation of coupled chemical reactions. *The Journal of*
550 *Physical Chemistry* **81**, 2340-2361, doi:10.1021/j100540a008 (1977).

- 551 62 Stefan Behnel, R. B., Dag Sverre Seljebotn, Greg Ewing, et al. *The Cython compiler*,
552 <<http://cython.org>.> (2008).
553 63 E Jones, T. O., P Peterson, et al. Scipy: Open source scientific tools for python [software].
554 (2001).
555 64 Cumming, G., Fidler, F. & Vaux, D. L. Error bars in experimental biology. *J Cell Biol* **177**,
556 7-11, doi:10.1083/jcb.200611141 (2007).
557